← Leaderboards
Timothy C Thompson
Baylor College Of Medicine
$13,464,867
Attributed
$13,860,035
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,465,579 · 15
By mechanism
P50$34,235,788 · 10
R01$8,439,455 · 3
R21$790,336 · 2
Top collaborators
- Christopher J. Logothetis6 shared
- John Davis2 shared
- Samir M Hanash2 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Peter T Scardino$5,501,749
- Vlad C Sandulache$3,056,791
- Adrian Philip Gee$19,740,990
- Yuan-Hung Lo$1,480,985
- Norman Michael Greenberg$14,007,258
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateSignal TransductionClinical ResearchProstate NeoplasmsMediatingBaseMolecularTumorCancer PatientPathway InteractionsProstateCancer CenterMalignant NeoplasmsIn VitroGrowthResponseDna DamageGene ExpressionAnticancer ResearchTumor Suppressor GenesNeoplasm /Cancer GeneticsPrincipal InvestigatorBiologicalGene Targeting
Grant awards (76)
Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer$668,323
R01 · FY2025 · CA · contact PI
Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer$634,907
R01 · FY2024 · CA · contact PI
Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer$668,323
R01 · FY2023 · CA · contact PI
Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPORE$664,838
P50 · FY2022 · CA
Targeting Androgen Receptor and PARP for Synthetic Lethality in CRPC$309,148
P50 · FY2022 · CA · contact PI
Prostate cancer-associated SPOP mutations modulate innate immune response and immune checkpoint therapy$185,552
R21 · FY2022 · CA · contact PI
Prostate cancer-associated SPOP mutations modulate innate immune response and immune checkpoint therapy$227,205
R21 · FY2021 · CA · contact PI
MD Anderson Cancer Center Prostate Cancer SPORE$2,228,646
P50 · FY2020 · CA
Targeting Androgen Receptor and PARP for Synthetic Lethality in CRPC$288,977
P50 · FY2020 · CA · contact PI
Developmental Research Program$154,071
P50 · FY2020 · CA · contact PI
MD Anderson Cancer Center Prostate Cancer SPORE$2,235,720
P50 · FY2019 · CA
Targeting Androgen Receptor and PARP for Synthetic Lethality in CRPC$289,762
P50 · FY2019 · CA · contact PI
Lipidomics-based biomarkers for risk of progression in early prostate cancer$168,779
R21 · FY2019 · CA · contact PI
Developmental Research Program$154,856
P50 · FY2019 · CA · contact PI
MD Anderson Cancer Center Prostate Cancer SPORE$2,404,000
P50 · FY2018 · CA
Targeting Androgen Receptor and PARP for Synthetic Lethality in CRPC$308,459
P50 · FY2018 · CA · contact PI
Lipidomics-based biomarkers for risk of progression in early prostate cancer$208,800
R21 · FY2018 · CA · contact PI
Developmental Research Program$173,555
P50 · FY2018 · CA · contact PI
MD Anderson Cancer Center Prostate Cancer SPORE$2,357,537
P50 · FY2017 · CA
Targeting Androgen Receptor and PARP for Synthetic Lethality in CRPC$267,790
P50 · FY2017 · CA · contact PI
Developmental Research Program$155,727
P50 · FY2017 · CA · contact PI
MD Anderson Cancer Center Prostate Cancer SPORE$2,259,759
P50 · FY2016 · CA
Targeting Androgen Receptor and PARP for Synthetic Lethality in CRPC$328,821
P50 · FY2016 · CA · contact PI
Developmental Research Program$75,200
P50 · FY2016 · CA · contact PI
GLIPR1-ATM Protein Therapy for Prostate Cancer$235,187
P50 · FY2013 · CA · contact PI
Developmental Research Program$132,861
P50 · FY2013 · CA · contact PI
GLIPR1-ATM Protein Therapy for Prostate Cancer$259,381
P50 · FY2012 · CA · contact PI
Developmental Research Program$145,153
P50 · FY2012 · CA · contact PI
Mechanisms of Progression in Oncogene-Incuded Prostate Cancer$316,164
R01 · FY2011 · CA · contact PI
GLIPR1-ATM Protein Therapy for Prostate Cancer$250,238
P50 · FY2011 · CA · contact PI
Developmental Research Program$138,700
P50 · FY2011 · CA · contact PI
Mechanisms of Progression in Oncogene-Incuded Prostate Cancer$325,941
R01 · FY2010 · CA · contact PI
Mechanisms of Metastasis in Experimental Prostate Cancer$296,750
R01 · FY2010 · CA · contact PI
GLIPR1-ATM Protein Therapy for Prostate Cancer$254,274
P50 · FY2010 · CA · contact PI
Developmental Research Program$139,559
P50 · FY2010 · CA · contact PI
Mechanisms of Progression in Oncogene-Incuded Prostate Cancer$325,941
R01 · FY2009 · CA · contact PI
Mechanisms of Metastasis in Experimental Prostate Cancer$296,750
R01 · FY2009 · CA · contact PI
GLIPR1-ATM Protein Therapy for Prostate Cancer$254,334
P50 · FY2009 · CA · contact PI
Developmental Research Program$139,519
P50 · FY2009 · CA · contact PI
Mechanisms of Progression in Oncogene-Incuded Prostate Cancer$325,941
R01 · FY2008 · CA · contact PI
Mechanisms of Metastasis in Experimental Prostate Cancer$296,750
R01 · FY2008 · CA · contact PI
Mechanisms of Progression in Oncogene-Incuded Prostate Cancer$325,941
R01 · FY2007 · CA · contact PI
Mechanisms of Metastasis in Experimental Prostate Cancer$289,043
R01 · FY2007 · CA · contact PI
Mechanisms of Metastasis in Experimental Prostate Cancer$297,675
R01 · FY2006 · CA · contact PI
SPORE in Prostate Cancer$2,649,535
P50 · FY2005 · CA
Progression/Oncogene Induced Prostate Cancer$312,288
R01 · FY2005 · CA
SPORE in Prostate Cancer$109,635
P50 · FY2005 · CA
SPORE in Prostate Cancer$2,399,558
P50 · FY2004 · CA
Progression/Oncogene Induced Prostate Cancer$312,288
R01 · FY2004 · CA
MECHANISMS OF METASTASIS IN EXPERIMENTAL PROSTATE CANCER$302,738
R01 · FY2004 · CA
SPORE in Prostate Cancer$3,104,009
P50 · FY2003 · CA
Progression/Oncogene Induced Prostate Cancer$312,288
R01 · FY2003 · CA
MECHANISMS OF METASTASIS IN EXPERIMENTAL PROSTATE CANCER$302,738
R01 · FY2003 · CA
SPORE in Prostate Cancer$3,122,009
P50 · FY2002 · CA
Progression/Oncogene Induced Prostate Cancer$312,288
R01 · FY2002 · CA
MECHANISMS OF METASTASIS IN EXPERIMENTAL PROSTATE CANCER$302,738
R01 · FY2002 · CA
CAVEOLIN-1 AS A BIO-MARKER FOR PROSTATE CANCER$0
P50 · FY2002 · CA
DEVELOPMENTAL RESEARCH PROGRAM$0
P50 · FY2002 · CA
SPORE IN PROSTATE CANCER$2,877,148
P50 · FY2001 · CA
Progression/Oncogene Induced Prostate Cancer$312,115
R01 · FY2001 · CA
MECHANISMS OF METASTASIS IN EXPERIMENTAL PROSTATE CANCER$302,738
R01 · FY2001 · CA
SPORE IN PROSTATE CANCER$129,754
P50 · FY2001 · CA
GENE THERAPY FOR PROSTATE CANCER$0
P50 · FY2001 · CA
GENE THERAPY FOR PROSTATE CANCER$0
P50 · FY2001 · CA
SPORE IN PROSTATE CANCER$2,549,885
P50 · FY2000 · CA
MECHANISMS OF METASTASIS IN EXPERIMENTAL PROSTATE CANCER$302,484
R01 · FY2000 · CA
PROGRESSION MECHANISMS--ONCOGENE INDUCED PROSTATE CANCER$296,303
R01 · FY2000 · CA
SPORE IN PROSTATE CANCER$250,000
P50 · FY2000 · CA
GENE THERAPY FOR PROSTATE CANCER$174,672
P50 · FY2000 · CA
SPORE IN PROSTATE CANCER$126,304
P50 · FY2000 · CA
SPORE IN PROSTATE CANCER$74,687
P50 · FY2000 · CA
SPORE IN PROSTATE CANCER$62,520
P50 · FY2000 · CA
GENE THERAPY FOR PROSTATE CANCER$0
P50 · FY2000 · CA
GENE THERAPY FOR PROSTATE CANCER$0
P50 · FY2000 · CA
GENE THERAPY FOR PROSTATE CANCER$0
P50 · FY2000 · CA
GENE THERAPY FOR PROSTATE CANCER$0
P50 · FY2000 · CA